THE TAPE
VCYT · Medical Laboratories · $1.9B

Veracyte, Inc.

$24.01▼ −1.32%
Last close
Relative strength
3RS
of 99, against every stock▼ -55 on the month
Falling back
Strong industry, weak stock
−63.6%
six months against Medical Laboratories
52-week range
−60.6%
from the high
$21.91$60.91
Setup
On no screen
No base, flag or squeeze in place tonight. What is and is not there
No report date on the calendar.
Growth FLATProof SHOWN
Quarter to Sep 30, revenue +15% on a year ago
Why it is on no screen

VCYT is off the screens on 3 checks.

A base has formed19.6 weeks, from 21.91 to 60.91.
Long enough to count19.6 weeks against 3 needed.
Shallow enough64.0% deep against 35% allowed.
Close to its pivot-60.6% from the pivot; listed down to -20%.
Relative strengthRS 3 against 70 needed.

Measured against the base-and-breakout thresholds. The other screens use their own numbers, so a name can miss here and still be a fair-looking chart.

Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year
Support and resistance

No price has been tested three times in the last 120 sessions: it has not spent long enough in one range to form a level.

The read

Veracyte, Inc. is not on any of the screens right now. Its relative strength rating is 3, and it sits in Medical Laboratories.

Against its industry
Strong industry, weak stockBehind its industry over one and six months while the industry is fully aligned and ahead of the S&P 500.
One month against its industry
-45.6%
Three months against its industry
-47.6%
Six months against its industry
-63.6%

Read against an equal-weighted index of Medical Laboratories, which is +58.5% against the S&P 500 over six months Fully aligned.

Peers
Same theme
No themes — common and fine.
Catalyst roadmap

Nothing dated in the next three months that we can ingest automatically.

How it moves on earnings

On average 19.3% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$581.8M
+15.1% year on year
Operating margin
17.1%
gross 72.0%
Net margin
21.8%
Free cash flow
$161.9M
8.4% of market cap
Price to sales
3.32×
Price to earnings
15.2×

Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Nov 4
Key takeaway
Profitable and cash generating; the question is growth.
Revenue
$151.8M
+1.0% QoQ · +15.1% YoY
Gross margin
70.6%
-1.6 pts QoQ
Net income
$31.5M
Positive
Free cash flow
$37.9M
Cash generating

What the numbers say

  • Revenue +15.1% year over year, +1.0% on the quarter
  • Weak: Gross margin 70.6%, -1.6 points on the quarter
  • Good: Profitable: net income $32M, operating margin 10.9%
  • Good: Cash generating: operating cash flow $40M, free cash flow $38M
  • Good: Net cash $200M · cash $200M
Revenue by quarter
Free cash flow
Net income
shares +3.9% in a year · net cash $199.8M

The desk’s own read

Flagged as drifting down since the report

Final read
Growth: FLAT · Economic proof: SHOWN
Key question: Can the cash generation hold as growth slows?
The next test is gross margin: gross margin 70.6%, -1.6 points on the quarter.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

Held by 1 of 46 tracked funds at the end of Q3 2026.

Last quarter: 1 trimmed.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
GappedTape · 2026-11-11
-7.2%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
GappedTape · 2026-11-10
+7.3%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
New 52-week lowTape · 2026-11-06
11.5x vol
Mixed: stocks have outrun random stocks by 0.6% over three sessions, not consistently enough to call (746 cases over 51 nights). Against their own sector they have outrun by 0.2%.
Closed below its 20- and 50-day on heavy volumeTape · 2026-11-06
below 20d & 50d on 11.5x volume at 24.00
No measurable effect: stocks behave like random ones over the next three sessions (1,780 cases over 60 nights).
GappedTape · 2026-11-06
-54.3% ⚠ probable split/bad tick — the scanner believes this is a corporate action rather than a real move.
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Moved 5%+ down on earningsTape · 2026-11-06
-54.3% on earnings 2026-11-04
No measurable effect: stocks behave like random ones over the next three sessions (665 cases over 44 nights).
Unusual volumeTape · 2026-11-06
29.5 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.
Reported resultsFiling · 2026-11-05
2.02
No measurable effect: stocks behave like random ones over the next three sessions (2,340 cases over 54 nights).

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
Insiders
Bought on the open market
0
Sold on the open market
22
$12,100,284 total

Sold: Holstein Jens, EASTHAM KARIN, Bhanji Muna, Leite John, Febbo Phillip G., Chambers Rebecca, McGuire Annie, Stapley Marc, Wygant Jonathan.

Not counted above: 26 filings for awards, option exercises, gifts or shares withheld to pay tax. Those follow a vesting schedule nobody chose the timing of, and counting them as selling is how that number gets misread.

Most recent filings
2026-10-28 Wygant Jonathan · VP, Chief Accounting Officerwithheld for tax1,306$65,705
2026-10-27 Holstein Jens · Directoroption exercise7,500$264,750
2026-10-27 Holstein Jens · Directorsell7,500$375,000
2026-10-27 EASTHAM KARIN · Directoroption exercise10,000$270,100
2026-10-27 EASTHAM KARIN · Directorsell14,850$742,573
2026-10-19 Bhanji Muna · Directorsell1,864$81,457
2026-09-24 Holstein Jens · Directoroption exercise7,500$264,750
2026-09-24 Holstein Jens · Directorsell7,500$352,500

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

What analysts expect
Strong buy2
Buy7
Hold3
Sell0
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

No option open interest for this company. Most listed names have no options at all, and we only read chains for names carrying a dated event, so this is a normal reading rather than a fault.

X-ray

No completed base to compare this one with yet.

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
Veracyte, Inc. (VCYT) — The Tape